PTGS2 and central nervous system cancer: The aim of this study was to evaluate the anti-glioma properties of celecoxib, Fmoc-L-Leucine, or their mixture against showing COX-2 and PPARγ expression, temozolomide-resistant U-118 MG glioma cell line.